Viking Therapeutics (NASDAQ:VKTX - Get Free Report)'s stock had its "buy" rating restated by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $102.00 price objective on the biotechnology company's stock. HC Wainwright's price target would suggest a potential upside of 294.74% from the stock's current price.
A number of other research analysts also recently commented on VKTX. Piper Sandler reduced their target price on Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a report on Thursday, February 6th. Raymond James lifted their price target on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a report on Thursday, February 6th. Scotiabank began coverage on Viking Therapeutics in a research report on Thursday, February 13th. They set a "sector outperform" rating and a $102.00 price target on the stock. The Goldman Sachs Group began coverage on Viking Therapeutics in a research note on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 target price on the stock. Finally, Maxim Group decreased their price objective on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating for the company in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $89.75.
View Our Latest Report on VKTX
Viking Therapeutics Stock Performance
Shares of NASDAQ:VKTX opened at $25.84 on Thursday. The stock has a 50-day simple moving average of $26.66 and a 200-day simple moving average of $41.19. The stock has a market capitalization of $2.90 billion, a P/E ratio of -25.84 and a beta of 0.84. Viking Therapeutics has a 1 year low of $18.92 and a 1 year high of $81.86.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07). During the same period in the previous year, the firm posted ($0.26) earnings per share. Analysts predict that Viking Therapeutics will post -1.56 earnings per share for the current year.
Insider Transactions at Viking Therapeutics
In related news, Director Sarah Kathryn Rouan purchased 1,240 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average price of $24.15 per share, with a total value of $29,946.00. Following the purchase, the director now owns 1,240 shares of the company's stock, valued at $29,946. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 4.10% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in VKTX. Blue Trust Inc. grew its position in Viking Therapeutics by 75.9% during the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 309 shares in the last quarter. YANKCOM Partnership purchased a new position in shares of Viking Therapeutics during the fourth quarter valued at $33,000. Parallel Advisors LLC raised its position in Viking Therapeutics by 64.8% during the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock valued at $33,000 after buying an additional 536 shares during the period. FIL Ltd boosted its position in Viking Therapeutics by 116.8% during the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 648 shares during the period. Finally, NBC Securities Inc. grew its stake in Viking Therapeutics by 222,100.0% during the 1st quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 2,221 shares in the last quarter. 76.03% of the stock is owned by hedge funds and other institutional investors.
About Viking Therapeutics
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
